• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三阳性与雌激素受体阳性/孕激素受体阳性/人表皮生长因子受体2阴性乳腺癌亚型之间的临床病理特征差异及死亡风险

Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.

作者信息

Parise Carol A, Caggiano Vincent

机构信息

Sutter Institute for Medical Research, 2801 Capitol Ave, Suite 400, Sacramento, CA, 95816, USA.

出版信息

Cancer Causes Control. 2019 May;30(5):417-424. doi: 10.1007/s10552-019-01152-8. Epub 2019 Mar 16.

DOI:10.1007/s10552-019-01152-8
PMID:30879205
Abstract

PURPOSE

This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2- breast cancer subtypes.

METHODS

Cases of first primary female invasive TP and ER+/PR+/HER2- breast cancer were obtained from the California Cancer Registry. Logistic regression analysis was used to compare differences in factors associated with the TP versus the ER+/PR+/HER2- subtype. Cox regression was used to compute the adjusted risk of breast cancer-specific mortality of the TP versus ER+/PR+/HER2-.

RESULTS

The odds of TP versus ER+/PR+/HER2- were higher with advanced stage, high grade, low SES, ≤ 45 years of age (OR 1.48; CI 1.40-1.55), black (OR 1.11; CI 1.02-1.21), Asian/Pacific Islander (OR 1.15; CI 1.09-1.22), and uninsured (OR 1.42; CI 1.15-1.73). Unadjusted survival analysis indicated worse survival for the TP when compared with the ER+/PR+/HER2- subtype. However, adjusted risk of mortality for the TP subtype was not statistically significantly worse than the ER+/PR+/HER2- subtype.

CONCLUSIONS

Young age, advanced stage and grade, low SES, black and API race, and lack of health insurance are more common in the TP subtype than in the ER+/PR+/HER2- subtype. However the risk of mortality between these two subtypes is similar.

摘要

目的

本研究比较了三阳性（TP）和雌激素受体阳性/孕激素受体阳性/人表皮生长因子受体2阴性（ER+/PR+/HER2-）乳腺癌亚型之间的人口统计学和临床病理特征以及死亡风险。

方法

从加利福尼亚癌症登记处获取首次原发性女性浸润性TP和ER+/PR+/HER2-乳腺癌病例。采用逻辑回归分析比较TP与ER+/PR+/HER2-亚型相关因素的差异。采用Cox回归计算TP与ER+/PR+/HER2-相比的乳腺癌特异性死亡调整风险。

结果

TP与ER+/PR+/HER2-相比，在晚期、高级别、低社会经济地位、年龄≤45岁（比值比[OR]1.48；可信区间[CI]1.40 - 1.55）、黑人（OR 1.11；CI 1.02 - 1.21）、亚裔/太平洋岛民（OR 1.15；CI 1.09 - 1.22）以及未参保人群（OR 1.42；CI 1.15 - 1.73）中出现的几率更高。未经调整的生存分析表明，与ER+/PR+/HER2-亚型相比，TP的生存率更差。然而，TP亚型的死亡调整风险在统计学上并不比ER+/PR+/HER2-亚型显著更差。

结论

TP亚型中年轻、晚期和高级别、低社会经济地位、黑人及亚裔/太平洋岛民种族以及缺乏医疗保险的情况比ER+/PR+/HER2-亚型更为常见。然而，这两种亚型之间的死亡风险相似。

相似文献

1
Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes.三阳性与雌激素受体阳性/孕激素受体阳性/人表皮生长因子受体2阴性乳腺癌亚型之间的临床病理特征差异及死亡风险
Cancer Causes Control. 2019 May;30(5):417-424. doi: 10.1007/s10552-019-01152-8. Epub 2019 Mar 16.
2
Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.加利福尼亚州亚裔美国人中雌激素受体/孕激素受体/人表皮生长因子受体2乳腺癌亚型的患病风险差异。
Cancer Epidemiol. 2014 Oct;38(5):556-62. doi: 10.1016/j.canep.2014.08.001. Epub 2014 Sep 22.
3
Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.加利福尼亚州 1999-2004 年浸润性乳腺癌女性中，根据雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体 2（HER2）定义的乳腺癌亚型。
Breast J. 2009 Nov-Dec;15(6):593-602. doi: 10.1111/j.1524-4741.2009.00822.x. Epub 2009 Sep 17.
4
Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.7 年随访后年轻和老年女性全国队列中临床亚型的乳腺癌特异性生存。
Int J Cancer. 2019 Mar 15;144(6):1251-1261. doi: 10.1002/ijc.31950. Epub 2018 Dec 3.
5
Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.基于免疫组织化学亚型（ER/PR/HER2）的乳腺癌生存分析：一项回顾性队列研究。
Arch Iran Med. 2016 Oct;19(10):680-686.
6
Variation in breast cancer subtypes with age and race/ethnicity.乳腺癌亚型随年龄和种族/民族的变化。
Crit Rev Oncol Hematol. 2010 Oct;76(1):44-52. doi: 10.1016/j.critrevonc.2009.09.002. Epub 2009 Oct 2.
7
Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.生殖特征、绝经状态、种族和民族以及 ER、PR 和 HER2 状态定义的乳腺癌亚型风险：少数民族乳腺癌病因研究。
Breast Cancer Res. 2024 May 31;26(1):88. doi: 10.1186/s13058-024-01834-5.
8
Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.在一个多民族亚洲国家中，由雌激素受体、孕激素受体和人类生长因子受体-2所定义的乳腺癌预后情况。
World J Surg. 2015 Oct;39(10):2450-8. doi: 10.1007/s00268-015-3133-2.
9
Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.T1、T2 和 T3 期肿瘤中淋巴结阴性、ER/PR/HER2 阳性乳腺癌亚型的死亡风险。
Breast Cancer Res Treat. 2017 Oct;165(3):743-750. doi: 10.1007/s10549-017-4383-5. Epub 2017 Jul 8.
10
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.雌激素或孕激素受体阴性表达在腔面B型HER2阴性乳腺癌患者中的预后价值
World J Surg Oncol. 2016 Sep 13;14(1):244. doi: 10.1186/s12957-016-0999-x.

引用本文的文献

1
The inhibitory effect of trastuzumab on BT474 triple‑positive breast cancer cell viability is reversed by the combination of progesterone and estradiol.曲妥珠单抗对BT474三阳性乳腺癌细胞活力的抑制作用被孕酮和雌二醇的联合使用所逆转。
Oncol Lett. 2023 Nov 15;27(1):19. doi: 10.3892/ol.2023.14152. eCollection 2024 Jan.
2
Disease characteristics and mortality among Asian women with breast cancer.亚洲女性乳腺癌的疾病特征和死亡率。
Cancer. 2022 Mar 1;128(5):1024-1037. doi: 10.1002/cncr.34015. Epub 2021 Nov 18.
3
Poor-Prognosis Metastatic Cancers in Adolescents and Young Adults: Incidence Patterns, Trends, and Disparities.
青少年和年轻成人中预后不良的转移性癌症：发病模式、趋势和差异。
JNCI Cancer Spectr. 2021 Apr 27;5(3). doi: 10.1093/jncics/pkab039. eCollection 2021 Jun.
4
In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.在现代，乳腺癌的分期、分级和受体亚型对生存的重要性如何：一项基于人群的队列研究。
Breast Cancer Res. 2021 Feb 1;23(1):17. doi: 10.1186/s13058-021-01393-z.